Article Correctness Is Author's Responsibility: Fingolimod shows superior efficacy to interferon beta-1a in pediatric multiple sclerosis: the PARADIGMS trial

The article below may contain offensive and/or incorrect content.

Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower annualized rate of relapse and lower incidence of new lesions identified on T2-weighted magnetic resonance imaging (MRI) compared to interferon beta-1a.